| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 32 | 2024 | 373 | 8.390 |
Why?
|
| Multiple Sclerosis | 12 | 2024 | 335 | 7.060 |
Why?
|
| Dementia | 24 | 2021 | 450 | 7.020 |
Why?
|
| Cholinergic Antagonists | 14 | 2024 | 51 | 6.690 |
Why?
|
| Nursing Homes | 24 | 2021 | 95 | 6.580 |
Why?
|
| Urinary Bladder, Overactive | 8 | 2021 | 28 | 5.410 |
Why?
|
| Cholinesterase Inhibitors | 8 | 2024 | 100 | 4.450 |
Why?
|
| Medicare | 22 | 2024 | 424 | 3.680 |
Why?
|
| Depression | 16 | 2020 | 1244 | 3.670 |
Why?
|
| United States | 100 | 2024 | 10821 | 3.440 |
Why?
|
| Practice Patterns, Physicians' | 20 | 2024 | 723 | 3.020 |
Why?
|
| Muscarinic Antagonists | 8 | 2024 | 38 | 3.010 |
Why?
|
| Aged | 96 | 2024 | 19549 | 2.930 |
Why?
|
| Drug Utilization | 15 | 2017 | 162 | 2.850 |
Why?
|
| Drug Prescriptions | 18 | 2023 | 221 | 2.840 |
Why?
|
| Psychotropic Drugs | 15 | 2019 | 124 | 2.770 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 788 | 2.670 |
Why?
|
| Psychotic Disorders | 10 | 2013 | 136 | 2.650 |
Why?
|
| Homes for the Aged | 8 | 2017 | 24 | 2.620 |
Why?
|
| Pneumonia | 5 | 2022 | 326 | 2.380 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 7 | 2017 | 226 | 2.310 |
Why?
|
| Ambulatory Care | 12 | 2021 | 387 | 2.190 |
Why?
|
| Retrospective Studies | 68 | 2024 | 16270 | 2.190 |
Why?
|
| Analgesics, Opioid | 10 | 2024 | 409 | 2.130 |
Why?
|
| Paroxetine | 4 | 2017 | 29 | 2.100 |
Why?
|
| Health Expenditures | 6 | 2024 | 103 | 2.080 |
Why?
|
| Fingolimod Hydrochloride | 4 | 2024 | 33 | 2.020 |
Why?
|
| Aged, 80 and over | 47 | 2024 | 6484 | 2.020 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2023 | 263 | 1.950 |
Why?
|
| Logistic Models | 26 | 2024 | 1807 | 1.940 |
Why?
|
| Central Nervous System Stimulants | 5 | 2017 | 126 | 1.870 |
Why?
|
| Humans | 163 | 2024 | 124482 | 1.850 |
Why?
|
| Prescription Drugs | 4 | 2023 | 53 | 1.800 |
Why?
|
| Male | 105 | 2024 | 61053 | 1.770 |
Why?
|
| Female | 109 | 2024 | 66319 | 1.750 |
Why?
|
| Polypharmacy | 7 | 2022 | 40 | 1.730 |
Why?
|
| Patient Readmission | 3 | 2022 | 383 | 1.620 |
Why?
|
| Cohort Studies | 28 | 2022 | 4751 | 1.620 |
Why?
|
| Medication Adherence | 7 | 2024 | 400 | 1.580 |
Why?
|
| Accidental Falls | 5 | 2024 | 104 | 1.580 |
Why?
|
| Health Care Surveys | 14 | 2021 | 286 | 1.580 |
Why?
|
| Cross-Sectional Studies | 28 | 2024 | 3426 | 1.530 |
Why?
|
| Machine Learning | 3 | 2023 | 242 | 1.490 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 125 | 1.480 |
Why?
|
| Cognitive Dysfunction | 3 | 2020 | 233 | 1.460 |
Why?
|
| Fractures, Bone | 4 | 2016 | 187 | 1.440 |
Why?
|
| Parkinson Disease | 4 | 2020 | 693 | 1.420 |
Why?
|
| Recurrence | 2 | 2024 | 1423 | 1.400 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2022 | 256 | 1.390 |
Why?
|
| Office Visits | 6 | 2020 | 77 | 1.370 |
Why?
|
| Dimethyl Fumarate | 3 | 2024 | 11 | 1.320 |
Why?
|
| Immunosuppressive Agents | 5 | 2024 | 644 | 1.310 |
Why?
|
| Adolescent | 46 | 2024 | 19301 | 1.280 |
Why?
|
| Medicaid | 14 | 2023 | 243 | 1.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2021 | 36 | 1.190 |
Why?
|
| Crotonates | 2 | 2024 | 6 | 1.120 |
Why?
|
| Quality of Life | 8 | 2022 | 1944 | 1.110 |
Why?
|
| Activities of Daily Living | 6 | 2022 | 404 | 1.080 |
Why?
|
| Hip Fractures | 2 | 2018 | 67 | 1.040 |
Why?
|
| Adult | 34 | 2024 | 29395 | 1.040 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 1158 | 1.030 |
Why?
|
| Middle Aged | 36 | 2024 | 26511 | 1.020 |
Why?
|
| Medication Errors | 4 | 2015 | 188 | 1.010 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 24 | 0.990 |
Why?
|
| Inappropriate Prescribing | 2 | 2015 | 41 | 0.970 |
Why?
|
| Heart Failure | 10 | 2023 | 2277 | 0.960 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 1327 | 0.950 |
Why?
|
| Antidepressive Agents | 7 | 2017 | 290 | 0.930 |
Why?
|
| Toluidines | 1 | 2024 | 3 | 0.910 |
Why?
|
| Risk | 12 | 2018 | 750 | 0.910 |
Why?
|
| Hydroxybutyrates | 1 | 2024 | 44 | 0.910 |
Why?
|
| Hypnotics and Sedatives | 2 | 2024 | 135 | 0.900 |
Why?
|
| Delirium | 1 | 2024 | 54 | 0.880 |
Why?
|
| Mental Disorders | 8 | 2024 | 824 | 0.880 |
Why?
|
| Longitudinal Studies | 10 | 2024 | 1322 | 0.870 |
Why?
|
| Nitriles | 1 | 2024 | 146 | 0.850 |
Why?
|
| Young Adult | 16 | 2024 | 8970 | 0.830 |
Why?
|
| Hospitalization | 12 | 2024 | 1775 | 0.830 |
Why?
|
| Case-Control Studies | 11 | 2024 | 3269 | 0.830 |
Why?
|
| Multivariate Analysis | 13 | 2016 | 1419 | 0.830 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 1911 | 0.800 |
Why?
|
| Propensity Score | 9 | 2017 | 212 | 0.770 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 162 | 0.750 |
Why?
|
| Biological Products | 1 | 2023 | 119 | 0.750 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2021 | 3 | 0.750 |
Why?
|
| Cognition | 3 | 2023 | 730 | 0.750 |
Why?
|
| Asthma | 2 | 2019 | 748 | 0.740 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 63 | 0.730 |
Why?
|
| Withholding Treatment | 2 | 2020 | 68 | 0.720 |
Why?
|
| Urological Agents | 1 | 2020 | 3 | 0.710 |
Why?
|
| Mandelic Acids | 1 | 2020 | 6 | 0.700 |
Why?
|
| Drug Therapy | 4 | 2008 | 85 | 0.700 |
Why?
|
| Comorbidity | 7 | 2020 | 1527 | 0.700 |
Why?
|
| Pyrrolidines | 1 | 2020 | 36 | 0.700 |
Why?
|
| Benzofurans | 1 | 2020 | 24 | 0.690 |
Why?
|
| Prevalence | 10 | 2021 | 2442 | 0.680 |
Why?
|
| Risk Factors | 17 | 2024 | 10181 | 0.670 |
Why?
|
| Drug Utilization Review | 3 | 2015 | 33 | 0.670 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2021 | 222 | 0.650 |
Why?
|
| Outpatients | 7 | 2023 | 255 | 0.650 |
Why?
|
| Prescriptions | 4 | 2024 | 40 | 0.640 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 227 | 0.640 |
Why?
|
| Immunologic Factors | 3 | 2024 | 174 | 0.620 |
Why?
|
| Residence Characteristics | 6 | 2019 | 272 | 0.610 |
Why?
|
| Cost of Illness | 1 | 2020 | 247 | 0.610 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 221 | 0.600 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 24 | 0.580 |
Why?
|
| Myasthenia Gravis | 1 | 2018 | 71 | 0.580 |
Why?
|
| Documentation | 1 | 2019 | 119 | 0.580 |
Why?
|
| Melanoma | 1 | 2024 | 832 | 0.580 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 511 | 0.570 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 803 | 0.570 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 441 | 0.560 |
Why?
|
| Age Factors | 10 | 2024 | 2810 | 0.560 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2019 | 112 | 0.560 |
Why?
|
| Child | 35 | 2024 | 24439 | 0.560 |
Why?
|
| Data Collection | 4 | 2013 | 383 | 0.560 |
Why?
|
| Patient Discharge | 2 | 2022 | 496 | 0.550 |
Why?
|
| Incidence | 10 | 2019 | 3093 | 0.550 |
Why?
|
| Bipolar Disorder | 6 | 2019 | 351 | 0.550 |
Why?
|
| Proton Pump Inhibitors | 2 | 2019 | 261 | 0.550 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 10 | 0.540 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 872 | 0.530 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.530 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 316 | 0.530 |
Why?
|
| Odds Ratio | 6 | 2021 | 1250 | 0.530 |
Why?
|
| Health Status | 2 | 2015 | 374 | 0.520 |
Why?
|
| Linear Models | 5 | 2023 | 672 | 0.520 |
Why?
|
| Disabled Persons | 1 | 2016 | 100 | 0.480 |
Why?
|
| Risk Adjustment | 1 | 2015 | 59 | 0.470 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 240 | 0.440 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2896 | 0.430 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 290 | 0.430 |
Why?
|
| Mortality | 1 | 2015 | 233 | 0.430 |
Why?
|
| Treatment Outcome | 11 | 2023 | 12315 | 0.420 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2017 | 27 | 0.420 |
Why?
|
| Neurodegenerative Diseases | 1 | 2015 | 252 | 0.410 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2023 | 128 | 0.400 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 459 | 0.400 |
Why?
|
| Galantamine | 2 | 2022 | 10 | 0.400 |
Why?
|
| Rivastigmine | 2 | 2022 | 17 | 0.400 |
Why?
|
| Osteoarthritis | 1 | 2013 | 86 | 0.390 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 15 | 0.380 |
Why?
|
| Depressive Disorder | 1 | 2015 | 456 | 0.380 |
Why?
|
| Healthcare Disparities | 5 | 2019 | 430 | 0.380 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 38 | 0.380 |
Why?
|
| Joint Diseases | 1 | 2011 | 33 | 0.380 |
Why?
|
| Home Care Services | 1 | 2012 | 69 | 0.370 |
Why?
|
| Indans | 2 | 2022 | 55 | 0.370 |
Why?
|
| Acetylcholinesterase | 2 | 2021 | 24 | 0.370 |
Why?
|
| Emergency Service, Hospital | 6 | 2024 | 1088 | 0.370 |
Why?
|
| Methotrexate | 2 | 2023 | 341 | 0.370 |
Why?
|
| Neoplasms | 2 | 2023 | 2784 | 0.360 |
Why?
|
| Cerebrovascular Disorders | 2 | 2010 | 122 | 0.360 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 606 | 0.350 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 631 | 0.350 |
Why?
|
| Risk Assessment | 5 | 2024 | 3392 | 0.350 |
Why?
|
| Steroids | 1 | 2011 | 203 | 0.350 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 94 | 0.350 |
Why?
|
| Geography | 3 | 2019 | 110 | 0.350 |
Why?
|
| Administration, Oral | 2 | 2024 | 678 | 0.350 |
Why?
|
| Sex Factors | 4 | 2024 | 1277 | 0.350 |
Why?
|
| Piperidines | 2 | 2022 | 204 | 0.340 |
Why?
|
| Off-Label Use | 1 | 2010 | 27 | 0.340 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2017 | 72 | 0.340 |
Why?
|
| Health Care Costs | 2 | 2024 | 370 | 0.330 |
Why?
|
| Drug Interactions | 3 | 2019 | 253 | 0.330 |
Why?
|
| Pediatrics | 1 | 2019 | 1154 | 0.320 |
Why?
|
| Drug Labeling | 1 | 2009 | 27 | 0.320 |
Why?
|
| Child Welfare | 1 | 2009 | 64 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 283 | 0.320 |
Why?
|
| Needs Assessment | 1 | 2009 | 175 | 0.300 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 54 | 0.300 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 288 | 0.290 |
Why?
|
| Hypertension | 3 | 2016 | 1289 | 0.290 |
Why?
|
| Propylamines | 1 | 2007 | 8 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 2 | 2009 | 206 | 0.270 |
Why?
|
| Time Factors | 6 | 2017 | 6285 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 1687 | 0.270 |
Why?
|
| Health Services Needs and Demand | 4 | 2015 | 174 | 0.250 |
Why?
|
| Benzodiazepines | 4 | 2012 | 101 | 0.250 |
Why?
|
| SEER Program | 2 | 2024 | 200 | 0.250 |
Why?
|
| Algorithms | 2 | 2023 | 1614 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 847 | 0.250 |
Why?
|
| Chronic Pain | 2 | 2024 | 129 | 0.240 |
Why?
|
| Health Surveys | 3 | 2012 | 244 | 0.240 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 3724 | 0.230 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 859 | 0.230 |
Why?
|
| Urinary Incontinence | 1 | 2024 | 70 | 0.230 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2024 | 35 | 0.220 |
Why?
|
| Naloxone | 1 | 2024 | 47 | 0.220 |
Why?
|
| Databases, Factual | 3 | 2016 | 1178 | 0.220 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 401 | 0.220 |
Why?
|
| Pain | 3 | 2024 | 457 | 0.220 |
Why?
|
| Fees, Pharmaceutical | 1 | 2003 | 1 | 0.220 |
Why?
|
| Acute Pain | 1 | 2023 | 21 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 306 | 0.210 |
Why?
|
| Atomoxetine Hydrochloride | 2 | 2017 | 15 | 0.210 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 69 | 0.210 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2022 | 7 | 0.210 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2022 | 24 | 0.200 |
Why?
|
| Medicare Part D | 2 | 2015 | 17 | 0.200 |
Why?
|
| Geriatrics | 1 | 2003 | 73 | 0.200 |
Why?
|
| Cannabidiol | 1 | 2022 | 22 | 0.200 |
Why?
|
| Anxiety | 4 | 2011 | 967 | 0.200 |
Why?
|
| Pharmacists | 3 | 2000 | 84 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 1 | 2004 | 218 | 0.200 |
Why?
|
| Glatiramer Acetate | 1 | 2022 | 11 | 0.200 |
Why?
|
| Child Psychiatry | 2 | 2024 | 16 | 0.200 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 5125 | 0.200 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 251 | 0.200 |
Why?
|
| Managed Care Programs | 2 | 2019 | 61 | 0.190 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 3 | 0.190 |
Why?
|
| Diltiazem | 1 | 2021 | 13 | 0.190 |
Why?
|
| Sitagliptin Phosphate | 1 | 2021 | 7 | 0.190 |
Why?
|
| Referral and Consultation | 1 | 2005 | 539 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 148 | 0.190 |
Why?
|
| Body Mass Index | 4 | 2023 | 1556 | 0.190 |
Why?
|
| Citalopram | 1 | 2021 | 30 | 0.180 |
Why?
|
| Sotalol | 1 | 2021 | 33 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2024 | 548 | 0.180 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 25 | 0.180 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 112 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 334 | 0.180 |
Why?
|
| Models, Economic | 2 | 2020 | 51 | 0.180 |
Why?
|
| Professional Autonomy | 1 | 2001 | 27 | 0.180 |
Why?
|
| Injections | 1 | 2021 | 154 | 0.180 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 80 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2023 | 383 | 0.180 |
Why?
|
| Metformin | 1 | 2022 | 148 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2021 | 316 | 0.170 |
Why?
|
| Quetiapine Fumarate | 2 | 2012 | 16 | 0.170 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 14 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2020 | 1190 | 0.170 |
Why?
|
| Nurse Practitioners | 1 | 2001 | 46 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 368 | 0.170 |
Why?
|
| Hospitals | 1 | 2022 | 398 | 0.170 |
Why?
|
| Physician Assistants | 1 | 2001 | 68 | 0.170 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2022 | 208 | 0.160 |
Why?
|
| Pharmacy Service, Hospital | 2 | 1996 | 49 | 0.160 |
Why?
|
| Schools, Pharmacy | 1 | 2019 | 22 | 0.160 |
Why?
|
| Risperidone | 2 | 2012 | 60 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2000 | 173 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 1251 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2015 | 775 | 0.160 |
Why?
|
| Weight Gain | 2 | 2019 | 405 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 1999 | 26 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 151 | 0.160 |
Why?
|
| Drug Monitoring | 3 | 2024 | 169 | 0.160 |
Why?
|
| Quality of Health Care | 2 | 2019 | 391 | 0.160 |
Why?
|
| Vomiting | 1 | 1999 | 107 | 0.160 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 54 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 180 | 0.150 |
Why?
|
| Medical Errors | 1 | 2000 | 155 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 211 | 0.140 |
Why?
|
| Sinusitis | 1 | 2019 | 117 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 251 | 0.140 |
Why?
|
| Societies, Pharmaceutical | 1 | 1996 | 11 | 0.140 |
Why?
|
| Amitriptyline | 3 | 2002 | 27 | 0.130 |
Why?
|
| Prognosis | 2 | 2023 | 4572 | 0.130 |
Why?
|
| Child, Preschool | 6 | 2023 | 14043 | 0.130 |
Why?
|
| Research Design | 1 | 2020 | 690 | 0.130 |
Why?
|
| Interviews as Topic | 2 | 2024 | 377 | 0.130 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 94 | 0.130 |
Why?
|
| Models, Statistical | 2 | 2015 | 471 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 294 | 0.130 |
Why?
|
| Medicare Part C | 1 | 2016 | 37 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 236 | 0.120 |
Why?
|
| Causality | 1 | 2015 | 83 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2020 | 723 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2018 | 256 | 0.120 |
Why?
|
| Disease Progression | 1 | 2021 | 2040 | 0.120 |
Why?
|
| Behavior | 1 | 2015 | 74 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2023 | 1128 | 0.120 |
Why?
|
| Epilepsy | 1 | 2022 | 872 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 306 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1600 | 0.120 |
Why?
|
| Clostridium Infections | 1 | 2018 | 245 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 530 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2015 | 193 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2015 | 120 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2018 | 366 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 271 | 0.110 |
Why?
|
| Pharmaceutical Services | 2 | 2019 | 35 | 0.110 |
Why?
|
| Infant | 5 | 2023 | 12473 | 0.110 |
Why?
|
| Medical Records | 2 | 2007 | 191 | 0.110 |
Why?
|
| Analgesics | 2 | 2024 | 132 | 0.100 |
Why?
|
| Affect | 1 | 2014 | 159 | 0.100 |
Why?
|
| Dyslipidemias | 1 | 2015 | 227 | 0.100 |
Why?
|
| Peptic Ulcer | 2 | 2019 | 148 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 581 | 0.100 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 43 | 0.100 |
Why?
|
| Foster Home Care | 1 | 2012 | 20 | 0.100 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 111 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2023 | 241 | 0.090 |
Why?
|
| Losartan | 1 | 2011 | 35 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 57 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2015 | 484 | 0.090 |
Why?
|
| Arthritis | 1 | 2011 | 81 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 111 | 0.090 |
Why?
|
| Tetrazoles | 1 | 2011 | 67 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 478 | 0.090 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 261 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 414 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 231 | 0.090 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 8 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2011 | 133 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 2505 | 0.090 |
Why?
|
| Texas | 4 | 2019 | 3588 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1025 | 0.080 |
Why?
|
| Legislation, Drug | 1 | 2009 | 9 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2127 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 191 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 398 | 0.080 |
Why?
|
| Social Behavior | 1 | 2010 | 209 | 0.080 |
Why?
|
| Financing, Personal | 1 | 2008 | 10 | 0.080 |
Why?
|
| Canada | 1 | 2009 | 298 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 728 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 24 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 283 | 0.070 |
Why?
|
| Demography | 2 | 1999 | 240 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8180 | 0.060 |
Why?
|
| Life Style | 1 | 2008 | 410 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 42 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 441 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 301 | 0.060 |
Why?
|
| Parents | 1 | 2012 | 1029 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 323 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 224 | 0.060 |
Why?
|
| Primary Health Care | 2 | 2021 | 774 | 0.060 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 4 | 0.060 |
Why?
|
| Nonprescription Drugs | 1 | 2024 | 50 | 0.050 |
Why?
|
| Drug Overdose | 1 | 2024 | 65 | 0.050 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 10 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 61 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 107 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1330 | 0.050 |
Why?
|
| Pain Management | 1 | 2024 | 181 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 826 | 0.050 |
Why?
|
| Doxepin | 1 | 2002 | 1 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 123 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2001 | 10 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 531 | 0.040 |
Why?
|
| Obesity | 1 | 2012 | 2267 | 0.040 |
Why?
|
| Utilization Review | 1 | 2000 | 39 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2000 | 65 | 0.040 |
Why?
|
| Physicians, Family | 1 | 2000 | 37 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 74 | 0.040 |
Why?
|
| Louisiana | 2 | 1996 | 135 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2022 | 379 | 0.040 |
Why?
|
| Pharmacy | 1 | 2019 | 13 | 0.040 |
Why?
|
| Chlordiazepoxide | 1 | 1999 | 1 | 0.040 |
Why?
|
| Dextropropoxyphene | 1 | 1999 | 3 | 0.040 |
Why?
|
| Diazepam | 1 | 1999 | 21 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 34157 | 0.040 |
Why?
|
| Dipyridamole | 1 | 1999 | 29 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 12 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 514 | 0.040 |
Why?
|
| Health Services Research | 1 | 2000 | 188 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 58 | 0.040 |
Why?
|
| Students, Pharmacy | 1 | 2019 | 63 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 1998 | 132 | 0.040 |
Why?
|
| Contraindications | 1 | 1997 | 78 | 0.040 |
Why?
|
| Seizures | 1 | 2022 | 878 | 0.030 |
Why?
|
| Leadership | 1 | 2019 | 228 | 0.030 |
Why?
|
| Emergencies | 1 | 1998 | 173 | 0.030 |
Why?
|
| Survival Rate | 2 | 2019 | 2028 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 425 | 0.030 |
Why?
|
| Salaries and Fringe Benefits | 1 | 1996 | 28 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 582 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1004 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 505 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 51 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 68 | 0.020 |
Why?
|
| Models, Structural | 1 | 2011 | 50 | 0.020 |
Why?
|
| Valsartan | 1 | 2011 | 25 | 0.020 |
Why?
|
| Fosinopril | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lisinopril | 1 | 2011 | 25 | 0.020 |
Why?
|
| Enalapril | 1 | 2011 | 18 | 0.020 |
Why?
|
| Captopril | 1 | 2011 | 28 | 0.020 |
Why?
|
| Veterans | 2 | 2011 | 1757 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2868 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 27 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 671 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 6082 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1997 | 30 | 0.010 |
Why?
|
| Health Services | 1 | 1997 | 71 | 0.010 |
Why?
|